Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Australia - English - Department of Health (Therapeutic Goods Administration)

aa-med pty ltd - 61127 - glaucoma shunt - for use in patients with medically uncontrollable glaucoma and poor surgical outcomes. this includes but is not limited to: neovascular glaucoma, aphakic/psudophakic glaucoma, patients who have failed conventional surgery, congenital glaucoma and secondary glaucoma due to uveitis, epithelial downgrowth, etc.

Australia - English - Department of Health (Therapeutic Goods Administration)

compliance management solutions - 63567 - glaucoma supraciliary implant - miniject is an integrated system for minimally invasive glaucoma surgery (migs). it consists of a glaucoma drainage implant, and a delivery system. the implant is composed of medical-grade silicone which has a precise porous microstructure and is 5.0 mm long with an oblong cross section of 1.1 x 0.6 mm. it has a green marker (0.4 mm wide) on the proximal end of the implant (?coloured ring?) that serves as a visual aid to assist with proper implantation depth in the supraciliary space. miniject is intended to be used to reduce intraocular pressure (iop) by channelling aqueous

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetazolamide sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

rqsolutions medical devices distribution support - 61127 - glaucoma shunt - the microshunt is intended for reduction of intraocular pressure in eyes of patients with primary open angle glaucoma where iop remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - acetazolamide, quantity: 250 mg - tablet, uncoated - excipient ingredients: maize starch; calcium hydrogen phosphate dihydrate; magnesium stearate; povidone; sodium starch glycollate - for adjunctive treatment of oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open angle) glaucoma, secondary glaucoma and preoperatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - acetazolamide - tablets - acetazolamide 250 mg - acetazolamide - acetazolamide - for adjunctive treatment of drug induced edema and edema due to congestive heart failure. chronic simple (open angle) glaucoma, secondary glaucoma and pre operatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. acute mountain sickness.

Australia - English - Department of Health (Therapeutic Goods Administration)

rqsolutions medical devices distribution support - 61127 - glaucoma shunt - the istent inject trabecular micro-bypass stent system, contains two titanium micro? stents that are thinly coated with stearalkonium heparin and preloaded onto a single use inserter. the stents are designed to create a patent opening from the anterior chamber into the trabecular meshwork and schlemm' s canal to enhance aqueous outflow and reduce intraocular pressure. the stent system is provided sterile. the istent inject trabecular micro-bypass system is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate primary open-angle glaucoma (poag) currently treated with ocular hypotensive medication. the device can be implanted with or without cataract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

rqsolutions medical devices distribution support - 62945 - glaucoma micro-stent - the product is designed to implant stents via an injector into schlemm?s canal, creating a patent opening in the trabecular meshwork to re-establish normal physiological outflow the istent inject w system trabecular micro-bypass system is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate primary open-angle glaucoma (poag) currently treated with ocular hypotensive medication. the device can be implanted with or without cataract surgery

United States - English - NLM (National Library of Medicine)

newton laboratories, inc. - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), gold (unii: 79y1949pyo) (gold - unii:79y1949pyo), atropa belladonna (unii: wqz3g9pf0h) (atropa belladonna - unii:wqz3g9pf0h), causticum (unii: dd5fo1wkfu) (causticum - unii:dd5fo1wkfu), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), colchicum autumnale bulb (unii: 993qhl78e6) (colchicum autumnale bulb - unii:993qhl78e6), euphrasia stricta (unii: c9642i91wl) (euphrasia stricta - uni - aconitum napellus 15 [hp_x] in 1 g - glaucoma   formulated for associated symptoms such as increased intraocular pressure, swelling of eyes, atrophy of optic nerve and narrow field of vision. formulated for associated symptoms such as increased intraocular pressure, swelling of eyes, atrophy of optic nerve and narrow field of vision.